rasagiline has been researched along with Behavior Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kulisevsky, J; Pagonabarraga, J | 1 |
| Maruyama, W; Naoi, M | 1 |
2 review(s) available for rasagiline and Behavior Disorders
| Article | Year |
|---|---|
[Dopaminergic treatment in Parkinson's disease: what has each therapeutic family got to offer?].
Topics: Amantadine; Antiparkinson Agents; Cardiovascular Diseases; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Clinical Trials as Topic; Dopamine Agonists; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Food-Drug Interactions; Humans; Indans; Indoles; Levodopa; Mental Disorders; Monoamine Oxidase Inhibitors; Multicenter Studies as Topic; Parkinson Disease; Serotonin Syndrome; Treatment Outcome | 2014 |
''70th Birthday Professor Riederer'' induction of glial cell line-derived and brain-derived neurotrophic factors by rasagiline and (-)deprenyl: a way to a disease-modifying therapy?
Topics: Animals; Brain-Derived Neurotrophic Factor; Dose-Response Relationship, Drug; Gene Expression Regulation; Glial Cell Line-Derived Neurotrophic Factor; Haplorhini; Humans; Indans; Mental Disorders; Monoamine Oxidase Inhibitors; Selegiline; Time Factors | 2013 |